Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Oct 29;21(1):1161.
doi: 10.1186/s12885-021-08840-2.

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

F J Hinsenveld  1 , B J Noordman  2 , J L Boormans  3 , J Voortman  4 , G J L H van Leenders  5 , S L van der Pas  6 , S C van Beek  2 , D E Oprea-Lager  7 , A N Vis  8
Affiliations
Clinical Trial

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

F J Hinsenveld et al. BMC Cancer. .

Abstract

Background: The recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20-40% of patients experience a complete pathological response (pCR) in the RC specimen and these patients have excellent long-term overall survival. Subject to debate is, however, whether patients with a pCR to NAC benefit from RC, which is a major surgical procedure with substantial morbidity, and if these patients might be candidates for close surveillance instead. However, currently it is not possible to accurately identify patients with a pCR to NAC in whom RC might be withheld. The objective of this study is to assess whether pathological response in the RC specimen after NAC can be predicted based on clinical, radiological, and histological variables and on a wide set of molecular biomarkers assessed in tissue, blood and urine.

Methods: This is a multicentre, prospective cohort study, including patients with cT2a-T4a N0-N1 M0 urothelial cell MIBC who are scheduled to undergo cisplatin-based NAC followed by RC. Prior to start of therapy, a 2-Deoxy-2-[18F] fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is performed. Response to NAC is evaluated by CT-scan. Blood and urine, including cytology, are prospectively collected for biomarker analyses before and after NAC. Immediately before RC, participants undergo cystoscopy with bimanual examination and a re-staging transurethral resection (TUR) of all visible cancerous lesions or with biopsies from scar tissue. Subsequently, RC is performed in all patients. Tissue from the diagnostic TUR, the re-staging TUR, and the RC specimen is examined for the presence of urothelial cancer carcinoma and DNA and RNA is isolated for molecular analysis. The primary endpoint is the pathological stage (ypTN) in the RC and ePLND specimen and its association with clinical response.

Discussion: If the PRE-PREVENCYS trial shows that the absence of residual disease after NAC in patients with MIBC is accurately predicted, a randomized controlled trial is scheduled comparing the overall survival of NAC plus RC versus NAC followed by close surveillance for patients with a clinically complete response (PREVENCYS trial).

Trial registration: Netherlands Trial Register: NL8678; Registered 20 May 2020 https://www.trialregister.nl/trial/8678.

Keywords: Bladder cancer; Bladder-sparing; Cancer biomarkers; Cystectomy; Neoadjuvant chemotherapy; Residual tumour.

PubMed Disclaimer

Conflict of interest statement

BJN is Associate Editor of BMC Cancer. All other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study algorithm of the PRE-PREVENCYS trial with expected distribution of patients. BME: bimanual examination; CRE: clinical response evaluation; CT: computed tomography; ddMVAC: dose-dense Methotrexate, Vinblastine, Adriamycin and Cisplatin; ePLND: extended pelvic lymph node dissection; FDG: 18F-fluoro-2-deoxy-D-glucose; Gem/Cis: Gemcitabine/Cisplatin; NAC: neoadjuvant chemotherapy; PET: positron-emission tomography; RC: radical cystectomy; TUR: transurethral resection
See this image and copyright information in PMC

References

    1. www.cijfersoverkanker.nl [updated 1-1-2020; cited 12-5-2021. Available from: https://iknl.nl/kankersoorten/blaaskanker/registratie/incidentie.
    1. Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder Cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi: 10.1016/j.eururo.2020.03.055. - DOI - PubMed
    1. Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–994. doi: 10.1016/j.juro.2010.05.037. - DOI - PubMed
    1. Porter MP, Gore JL, Wright JL. Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World J Urol. 2011;29(1):73–77. doi: 10.1007/s00345-010-0626-3. - DOI - PubMed
    1. Hautmann RE, De Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61(5):1039–1047. doi: 10.1016/j.eururo.2012.02.028. - DOI - PubMed

MeSH terms